Company Overview of Dezima Pharma B.V.
Dezima Pharma B.V. develops novel compounds for treatment of cardiovascular disease related to dyslipidemia. The company is based in Naarden, the Netherlands.
Naarden, 1411 DC
Key Executives for Dezima Pharma B.V.
Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
Dezima Pharma B.V. Key Developments
Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995
Jan 13 14
Dezima Pharma announced the completed enrolment of its phase 2b TULIP study. The aim of the study is to investigate the effects of TA-8995 (DEZ-001), a potential best-in-class CETP inhibitor, in around 360 patients with mild dyslipidemia on a wide range of plasma lipids, lipoproteins and validated biomarkers of cardiovascular disease (CVD). Recruitment for the double-blind, placebo-controlled, phase 2b dose ranging study of TA-8995 started in August 2013. The study has seen rapid enrolment in 17 specialized centres across the Netherlands and Denmark. The study has nine arms with patients receiving TA-8995 alone and in combination with statins. In addition, Dezima Pharma is currently preparing and executing a range of pre-clinical and clinical phase 3 enabling studies around its lead product, including a DDI study and a TQT study under an IND, in order to have a comprehensive partnering package.
Dezima Pharma Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001
Aug 29 13
Dezima Pharma B.V. announced the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease (CVD) in patients with mild dyslipidemia. The TULIP ("TA-8995: its Use in patients with mild dysLIPidemia") study will take place in specialized centres across Denmark and the Netherlands and will investigate the effects of different doses of DEZ-001 on established CVD biomarkers over a 3 month dosing period. DEZ-001 is a CETP inhibitor that has already demonstrated clinically relevant improvements on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels as well as other lipid parameters in healthy volunteers.
Dezima Pharma Announces Executive Changes
Jun 12 13
Dezima Pharma announced that it has appointed Rob de Ree as its new Chief Executive Officer. Mr. de Ree has over 20 years of experience in sales & marketing, business development and general management in Pharma and Medtech, including Medtronic. Most recently he held the CEO position at Amsterdam-based cardiovascular monitoring company.
Mr. de Ree is taking over from the company's interim CEO and General Partner of Forbion Capital Partners, Sander van Deventer, who has stepped down from the role, but will remain closely involved with the company by joining the Scientific Advisory Board.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries